非小细胞肺癌EGFR-TKI耐药机制及治疗的研究进展

Research progress of resistance mechanism and overcoming strategies of EGFR-TKI in non-small cell lung cancer

肺癌是全球发病率和病死率均位居前列的一种肿瘤,严重危害人类健康。其中,非小细胞肺癌(NSCLC)患者占80%~85%。表皮生长因子受体(EGFR)突变是NSCLC中最常见的基因突变类型之一,也是NSCLC治疗的重要靶点。表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)是EGFR敏感突变NSCLC患者的一线选择,然而,耐药不可避免。本文对NSCLC患者EGFR-TKI耐药机制及耐药后治疗的研究进展进行阐述。

Lung cancer is one of the most common malignancies with the highest incidence and mortality worldwide,which seriously endangers human health.Non-small cell lung cancer(NSCLC)accounts for 80%to 85%of all lung cancer patients.Epidermal growth factor receptor(EGFR)mutation is one of the most frequent genetic abnormalities in NSCLC,and is also an important target for NSCLC therapy.Epithelial growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)is the first-line treatment choice for NSCLC patients with EGFR-sensitive mutations.However,drug resistance is inevitable.This article reviews the research progress on the resistance mechanism and treatment strategies of EGFR-TKI in NSCLC.